Ovarian Neoplasms D010051

Related MeSH Hierarchy (7)

Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Neoplasms

Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female » Ovarian Neoplasms

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Ovarian Neoplasms

Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Ovarian Neoplasms

Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Ovarian Diseases » Ovarian Neoplasms

Description

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.   MeSH

Hierarchy View

Subtype Terms (9)

Brenner Tumor
22 drugs (16 approved, 6 experimental)

Carcinoma, Endometrioid
15 drugs (9 approved, 6 experimental)

Carcinoma, Ovarian Epithelial
108 drugs (50 approved, 58 experimental)


Phase 3 Indicated Drugs (90)

Phase 2 Indicated Drugs (360)

2x-121

7-hydroxystaurosporine

a166

abemaciclib (verzenio)

acalabrutinib (calquence)

acetylcysteine (mucomyst)

adavosertib

afatinib (gilotrif)

afuresertib

ak112

aldesleukin (proleukin)

alectinib (alecensa)

alemtuzumab (campath)

alendronic acid (fosamax)

alisertib

allogeneic hematopoietic stem cells (Hemacord)

allogeneic natural killer cells

allopurinol (zyloprim)

alpha-type-1-polarized dendritic cell

alvac(2)-ny-eso-1 (m)/tricom vaccine

alvocidib

aminocamptothecin

anastrozole (arimidex)

anetumab ravtansine

angiotensin 1-7

antineoplaston a10

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

apr-246

arsenic trioxide (trisenox)

atrasentan hydrochloride

auranofin (ridaura)

autologous dendritic cells loaded with autologous tumor lysate

autologous hematopoietic cell

autologous lymphocytes

autologous mesenchymal stem cells

autologous natural killer cells

autologous peripheral blood mononuclear cells

autologous tumor infiltrating lymphocytes

azacitidine (vidaza)

azd-4547

azd-5672

azd9150

BA3011

ba3021

bacille calmette-guerin

bax69

bbi503

becatecarin

belinostat (beleodaq)

bendamustine (treanda)

beractant (survanta)

bi-2536

bicalutamide (casodex)

birinapant

bortezomib (velcade)

br55

brostallicin

bryostatin

bupropion (wellbutrin)

cabazitaxel (jevtana kit)

cabozantinib (cometriq)

calcium

camptothecin

camrelizumab

cannabidiol (Epidiolex)

carboxyamidotriazole

carmustine (bicnu)

carotuximab

catumaxomab

cc-223

cdx-014

celecoxib (celebrex)

cemiplimab (libtayo)

ceralasertib

cetuximab (erbitux)

cobimetinib (cotellic)

copanlisib (aliqopa)

cotil-01

cp-18

cp-547632

crizotinib (xalkori)

crs-207

cyclosporine (sandimmune)

cyh33

cytokine induced killer cells

dabrafenib (tafinlar)

dactinomycin (cosmegen)

dalantercept

dalteparin (fragmin)

dasatinib (sprycel)

dc-006 vaccine

dcvac/ovca in parallel

dec-205/ny-eso-1 fusion protein cdx-1401

defactinib

deferasirox (exjade)

dendritic cells

dendritic cell tumor fusion vaccine

denenicokin

denileukin diftitox (ontak)

dexamethasone

dinitrophenyl

dipyridamole (persantine)

dkn-01

dolastatin

DP303c

dpx-survivac

ef5

elu001

emactuzumab

enadenotucirev

enmd 2076

enoxaparin (lovenox)

entinostat

entrectinib (Rozlytrek)

enzalutamide (xtandi)

enzastaurin

ep-100

epacadostat

epothilone

eribulin (halaven)

ertafolide

esg401

etirinotecan pegol (Onzeald)

everolimus (zortress)

exatecan mesylate

famitinib

fbp peptide

floxuridine (fudr)

fludarabine (fludara)

fluorouracil (efudex)

flutamide (eulexin)

folate-fluorescein conjugate

fondaparinux sodium (arixtra)

fowlpox-ny-eso-1 vaccine

fralpha peptide

fulvestrant (faslodex)

ganciclovir (cytovene)

ganetespib

ganitumab

gatipotuzumab

gefitinib (iressa)

glucose monohydrate

glufosfamide

goserelin (zoladex)

green tea

gsk-2636771

guadecitabine

her2/neu peptide

her-2/neu peptide vaccine

herpes simplex thymidine kinase

hla-mismatched donor peripheral stem cell infusion

hu3s193

hydroxychloroquine (plaquenil)

imatinib (gleevec)

imiquimod (aldara)

imp4297

incomplete freund's adjuvant

iniparib

interferon alpha-2a (roferon-a)

interferon alpha-2b (Intron-A)

interleukin-12

in vitro-treated bone marrow

in vitro-treated peripheral blood stem cell

ipatasertib

ipilimumab (yervoy)

irinotecan (Camptosar)

isis 5132

ispinesib

it-101

ixabepilone (ixempra)

jab-8263

ketoconazole (nizoral)

lag525

lapatinib (tykerb)

larotrectinib (vitrakvi)

lenalidomide (revlimid)

lenvatinib (lenvima)

leucovorin

liposomal lurtotecan

litronesib

lovastatin (mevacor)

lurtotecan

ly-295501

m6620

mage-3.a1 peptide

masitinib

matuzumab

medi0562

mercaptopurine (purinethol)

mesna (mesnex)

methylprednisolone (medrol)

mgi-114

mifepristone (mifeprex)

mitomycin (mutamycin)

mk-1775

modified vaccinia virus ankara vaccine expressing p53

motesanib

mpla

msk-2206

n-(4-hydroxyphenyl)all-trans retinamide

naltrexone (revia)

navitoclax

naxitamab

neoantigen reactive t cells

nerofe

ngr-htnf

nicotinamide

nivolumab (opdivo)

nk cell

norgestrel (Ovral)

ntx-301

nuc-1031

ny-eso-1

ny-eso-1 reactive tcr retroviral vector transduced autologous pbl

obi-821

ocoxin

olaratumab (lartruvo)

oleclumab

ombrabulin

omp-313m32

onapristone

onc201

oncolytic measles virus encoding thyroidal sodium iodide symporter

oncos-102

ondansetron (zofran)

oprelvekin (Neumega)

opt-822

orteronel

ose2101

osimertinib (tagrisso)

otl38

p53 peptide vaccine

p53-slp

palbociclib (ibrance)

panitumumab (vectibix)

pd-0360324

pegaspargase (oncaspar)

pegcetacoplan

peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1

peripheral blood lymphocytes

pexastimogene devacirepvec

pf-04878691

pf-07104091

phenylacetic acid (ucephan)

phenylacetylgluatmine

pimasertib

plevitrexed

plx2853

polyglutamate camptothecin

poly-iclc

prednisone (meticorten)

prexasertib

pumvc3-higfbp-2

quisinostat

ramucirumab (cyramza)

ras peptide cancer vaccine

recombinant adenoviral human p53 gene

recombinant vaccinia-ny-eso-1 vaccine

regn4018

regorafenib (stivarga)

relacorilant

relatlimab

rg-7599

ribociclib (kisqali)

rigosertib

rilotumumab

rintatolimod

ro4929097

rocuronium (zemuron)

romidepsin (istodax)

Phase 1 Indicated Drugs (257)


Organization Involved with Phase 3 Indications (152)

Organization Involved with Phase 2 Indications (372)

Abbott

AB Science

Accenture

Acerta Pharma

Adaptimmune

Aduro BioTech

Advent Health

AEterna Zentaris

AIT Strategies

Alcedis GmbH

AltaRex

Amarex Clinical Research

American Society of Clinical Oncology

Anchiano Therapeutics

Ångstrom Pharmaceuticals

Anhui Medical University

Aprea Therapeutics AB

Aqualis

Aravive Biologics

Aronex Pharmaceuticals

Asian Gynecologic Oncology Group

Assiut University

Astellas

Astex Pharmaceuticals, Inc.

Austin Health

AVAX Technologies

Aventis

AVEO Pharmaceuticals

Baxalta

Bayer

Baylor University

Bicycle Therapeutics

Billings Clinic

Biogen

Bionomics Limited

Boston Biomedical

Burzynski Research Institute

Butantan Institute

Caladrius Biosciences

California Cancer Center

Cancer Research Institute

Cancer Treatment Research Foundation

CASI Pharmaceuticals, Inc.

Catalysis SL

Cathay General Hospital

Catholic University of Korea

Catholic University of Sacred Heart, Rome

Cedars-Sinai Medical Center

Celgene

Cellectar, Inc

Celsion

Centocor

Centre Georges Francois Leclerc

Cephalon

Chang Gung University

Chao Family Comprehensive Cancer Center

Charles University

Chipscreen Biosciences, Ltd.

Chong Kun Dang Pharmaceutical

City of Hope National Medical Center

ClinAssess GmbH

Columbia University

Compugen

Context Therapeutics

Corcept Therapeutics

Corporacion Parc Tauli

Cristal Therapeutics

CTI BioPharma

Curie Institute

Cytran

Daiichi Sankyo

Department of Radiation Oncology

Dutch Cancer Society

East and North Hertfordshire NHS Trust

ECOG-ACRIN Cancer Research Group

Eisai

Eleison Pharmaceuticals

Ellipses Pharma

Emek Medical Center

Emory University

ENB Therapeutics, Inc

Esperance Pharmaceuticals Inc

Essex Pharma

European Commission

European Interbalkan Medical Center

ExcellaBio LLC

Exelixis

Facet Biotech

Free University of Brussels

French Cancer Research Hospital Program

Fresenius

Fundacion Instituto Valenciano de Oncologia

Gabrail Cancer Center

Garden State Cancer Center

GCIG: Gynecologic Cancer InterGroup

Genentech

Genmab

Genzyme

Georgetown University

George Washington University

Georgia Institute of Technology

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Ghent University

Government of Canada

Government of France

Government of Japan

Government of Singapore

Griffith University

Groupe Hospitalier Diaconesses Croix Saint Simon

Grupo Español de Tumores Huérfanos e Infrecuentes

Gynecologic Oncology Associates

Gynecologic Oncology Trial and Investigation Consortium, Japan

Harbin Medical University

Harrington Cancer Center

Hebrew University

Hellenic Cooperative Oncology Group

Hellenic Oncology Research Group

Hemispherx Biopharma

Henry M. Jackson Foundation for the Advancement of Military Medicine

Herbert Irving Comprehensive Cancer Center

Hoosier Cancer Research Network

Hospital A.C. Camargo

Hospital HM Universitario Sanchinarro

Hospital La Paz

Hospital Son Llatzer

Hospital Universitario Fundación Alcorcón

Hospital Universitario Madrid Sanchinarro

Hospital Universitari Son Dureta

HSK Research GmbH Wiesbaden

Icahn School of Medicine at Mount Sinai

Ignyta, Inc.

Imclone

Immetacyte

Immune System Key Ltd

Immunitor LLC

Immunovative Therapies

Immutep S.A.

Imperial College London

INC Research

Incyte

Indiana University

Innovation Pharmaceuticals

Inova Health System

Institut Gustave Roussy

Instituto de Investigação em Imunologia

Instituto de Medicina Integral Professor Fernando Figueira

Instituto Europeo de Oncologia

InterMune

Iovance

Iowa Methodist Medical Center

Ipsen

ISA Pharmaceuticals

ISTITUTO REGINA ELENA

James Graham Brown Cancer Center

Janssen Pharmaceutica NV

Japan Clinical Oncology Group

Jarrow Formulas Inc

Jiangsu Cancer Institute & Hospital

Jilin Provincial Tumor Hospital

Jinan University

Jubilant Innovation Ltd.

Kaiser Permanente

Kazia Therapeutics Limited

Kintara Therapeutics, Inc.

KK Women's and Children's Hospital

Korea Cancer Center Hospital

Korea Institute of Radiological & Medical Sciences (KIRAMS)

Krankenhaus der Barmherzigen Schwestern Linz

KuDOS

Kunming Medical University

Laekna Limited

Latin American Cooperative Oncology Group

Laval University

Leap Therapeutics, Inc.

Leiden University

LifeBridge Health

Ligue contre le cancer, France

Lowell General Hospital

Ludwig Institute for Cancer Research

Mackay Medical College

Marin Cancer Care

Mary Crowley Cancer Center

Mayo Clinic

McMaster University

Medical College of Wisconsin

Medical University Innsbruck

Medical University of South Carolina

MedImmune

MedServ. GmbH

Memorial Health University Medical Center

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Merck Serono

Mercy Medical Center

Merrimack Pharmaceuticals

Mersana Therapeutics

Mid-Atlantic Gynecologic Oncology & Pelvic Surgical Associates

Millennium Pharmaceuticals

MolMed S.p.A.

Morristown Memorial Hospital

Mount Sinai Hospital, Canada

Mundipharma

Nanjing Medical University

NanOlogy, LLC

NantWorks

National Cancer Institute, France

National Cheng Kung University

National Comprehensive Cancer Network

National Heart, Lung, and Blood Institute (NHLBI)

National Institutes of Health (NIH)

National University of Singapore

Nektar Therapeutics

Neovii Biotech

Newcastle University

NewLink Genetics Inc

New Mexico Cancer Care Alliance

NewVac LLC

New York Presbyterian Hospital

New York University

NextCure, Inc.

Nine Girls Ask

NKMAX Co., Ltd.

Northwest Biotherapeutics

NovoCure Ltd.

Novo Nordisk

Nucana

OBI Pharma, Inc

Ohio State University

OncoGenex Technologies

Oncology Venture

Onconova Therapeutics, Inc.

On Target Laboratories, LLC

Ontario Institute for Cancer Research

Onxeo

Ortho Biotech, Inc.

Osaka University

OSI Pharmaceuticals

Oxford BioMedica

People's Hospital of Leshan

Peter MacCallum Cancer Centre

PharmaBio Development Inc.

Philipps University of Marburg

Plexxikon

Premiere Oncology

Prescient Therapeutics, Ltd.

Prologue Research International

PsiOxus Therapeutics Ltd

Qingfeng Pharmaceutical Group

Quest PharmaTech Inc.

Region Syddanmark

Royal Marsden Hospital NHS Trust

Ruhr University Bochum

Russian Academy of Medical Sciences

Rutgers University

Saint Anne's Hospital

Samyang Biopharmaceuticals Corporation

San Antonio Military Medical Center

Scripps

Seattle Genetics

Shanghai Gynecologic Oncology Group

Shantou University

Shenzhen Geno-Immune Medical Institute

Shenzhen Hank Bioengineering Institute

SmithKline Beecham

Soochow University

Southeastern Gynecologic Oncology

South Plains Oncology Consortium

State University of New York, Buffalo

St. Joseph's Hospital and Medical Center - Phoenix, Arizona

Sunesis Pharmaceuticals

Sungkyunkwan University

Suzhou Medical College

Symphony Capital

Syndax Pharmaceuticals

Synteract, Inc.

Taiwanese Gynecologic Oncology Group

Takeda

Tapimmune Inc.

Technion University

Tel Aviv University

Temple University

Tennessee Oncology, PLLC

TetraLogic Pharmaceuticals

Texas Tech University

The Cancer Research Society

The Christie NHS Foundation Trust

The First People's Hospital of Changzhou

The University of Hong Kong

The University of Texas, Dallas

Thomas Jefferson University

Translational Research in Oncology

Tularik

United States Army

Universidad Autonoma de Barcelona

Universidad Autonoma de Madrid

Universidad de Cordoba

Universitario de Santiago, Spain

Universitätsklinikum Mannheim, Frauenklinik

University of Adelaide

University of Alabama, Birmingham

University of Alberta

University of Birmingham

University of Bologna

University of Brescia

University of British Columbia

University of Caen-Normandie

University of California, Irvine

University of California, San Diego

University of California, San Francisco

University of Cantabria

University of Connecticut

University of Crete

University of Electronic Science and Technology of China

University of Groningen

University of Haifa

University of Heidelberg

University of Illinois

University of Iowa

University of Kansas

University of Lausanne

University of Leicester

University of Liverpool

University of Louisville

University of Lyon

University of Maryland

University of Melbourne

University of Miami

University of Michigan

University of Minnesota

University of Montpellier

University of Montreal

University of New Mexico

University of North Carolina at Chapel Hill

University of Ottawa

University of Oxford

University of Pennsylvania

University of Pittsburgh

University of Queensland

University of South Carolina

University of Southern California

University of Southern Denmark

University of South Florida

University of Sydney

University of Texas at Houston

University of Texas, San Antonio

University of Toronto

University of Tsukuba

University of Ulsan

University of Utah

University of Valencia

University of Virginia

University of Warwick

University of Washington

University of Western Australia

University of Western Ontario

University of Wisconsin

University of Zaragoza

US Biotest

VentiRx Pharmaceuticals Inc.

Verastem, Inc.

Virginia Mason Medical Center

Vita-Salute University of Milano. Italy

Wake Forest University

Warwick Medical School

Washington University in St. Louis

Wayne State University

WiSP GmbH

Xiamen University

Yeshiva University

Yiling Pharmaceutical Inc.

Yonsei University

Ziopharm

Organization Involved with Phase 1 Indications (79)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.